AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...
Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.
A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.
Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...
With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).
The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...
BioCryst Pharmaceuticals has signed a definitive agreement to buy Astria Therapeutics with a mix of cash and stock ...
Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if ...
Nabla Bio has entered a new multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics ...
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...
A spike in licensing of candidates developed in China this year is a sign of the country’s transition in the global pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results